Các can thiệp điều trị dựa trên kháng thể: chiến lược tiềm năng để đối phó với nhiễm virus chikungunya

Akahata W, Yang ZY, Andersen H, Sun S, Holdaway HA, Kong WP, Lewis MG, Higgs S, Rossmann MG, Rao S, Nabel GJ (2010) A virus-like particle vaccine for epidemic chikungunya virus protects nonhuman primates against infection. Nat Med 16(3):334–338. https://doi.org/10.1038/nm.2105 Arevalo MT, Huang Y, Jones CA, Ross TM (2019) Vaccination with a chikungunya virus-like particle vaccine exacerbates disease in aged mice. PLoS Negl Trop Dis 13(4):e0007316. https://doi.org/10.1371/journal.pntd.0007316 Balazs AB, Ouyang Y, Hong CM, Chen J, Nguyen SM, Rao DS, An DS, Baltimore D (2014) Vectored immunoprophylaxis protects humanized mice from mucosal HIV transmission. Nat Med 20(3):296–300. https://doi.org/10.1038/nm.3471 Barr KL, Vaidhyanathan V (2019) Chikungunya in infants and children: is pathogenesis increasing? Viruses 11 Berkelman RL, Bryan RT, Osterholm MT, LeDuc JW, Hughes JM (1994) Infectious disease surveillance: a crumbling foundation. Science 264(5157):368–370 Bhooshan S, Gandhi KK, Godbole M, Dole SS, Kapur S, Prajna Satpathy AMK, Deshpande PS, Azad F, Gupte N, Bharadwaj R, Bollinger RC, Gupta A (2015) Dengue and Chikungunya co-infection associated with more severe clinical disease than mono-infection. Int J Healthc Biomed Res 03(03):117–123 Blutt SE, Conner ME (2013) The gastrointestinal frontier: IgA and viruses. Front Immunol 4:402. https://doi.org/10.3389/fimmu.2013.00402 Boonnak K, Slike BM, Burgess TH, Mason RM, Wu SJ, Sun P, Porter K, Rudiman IF, Yuwono D, Puthavathana P, Marovich MA (2008) Role of dendritic cells in antibody-dependent enhancement of dengue virus infection. J Virol 82(8):3939–3951. https://doi.org/10.1128/JVI.02484-07 Booth BJ, Ramakrishnan B, Narayan K, Wollacott AM, Babcock GJ, Shriver Z, Viswanathan K (2018) Extending human IgG half-life using structure-guided design. MAbs 10(7):1098–1110. https://doi.org/10.1080/19420862.2018.1490119 Broeckel R, Fox JM, Haese N, Kreklywich CN, Sukulpovi-Petty S, Legasse A, Smith PP, Denton M, Corvey C, Krishnan S, Colgin LMA, Ducore RM, Lewis AD, Axthelm MK, Mandron M, Cortez P, Rothblatt J, Rao E, Focken I, Carter K, Sapparapau G, Crowe JE Jr, Diamond MS, Streblow DN (2017) Therapeutic administration of a recombinant human monoclonal antibody reduces the severity of chikungunya virus disease in rhesus macaques. PLoS Negl Trop Dis 11(6):e0005637. https://doi.org/10.1371/journal.pntd.0005637 Burt FJ, Chen W, Miner JJ, Lenschow DJ, Merits A, Schnettler E, Kohl A, Rudd PA, Taylor A, Herrero LJ, Zaid A, Ng LFP, Mahalingam S (2017) Chikungunya virus: an update on the biology and pathogenesis of this emerging pathogen. Lancet Infect Dis 17(4):e107–e117. https://doi.org/10.1016/S1473-3099(16)30385-1 Campos GS, Albuquerque Bandeira AC, Diniz Rocha VF, Dias JP, Carvalho RH, Sardi SI (2017) First detection of chikungunya virus in breast milk. Pediatr Infect Dis J 36(10):1015–1017. https://doi.org/10.1097/INF.0000000000001658 Cardona-Correa SE, Castano-Jaramillo LM, Quevedo-Velez A (2017) Vertical transmission of chikungunya virus infection. Case report. Rev Chil Pediatr 88(2):285–288. https://doi.org/10.4067/S0370-41062017000200015 Chandak NH, Kashyap RS, Kabra D, Karandikar P, Saha SS, Morey SH, Purohit HJ, Taori GM, Daginawala HF (2009) Neurological complications of Chikungunya virus infection. Neurol India 57:177–180 Charrel RN, de Lamballerie X, Raoult D (2007) Chikungunya outbreaks--the globalization of vectorborne diseases. N Engl J Med 356(8):769–771. https://doi.org/10.1056/NEJMp078013 Chow A, Her Z, Ong EK, Chen JM, Dimatatac F, Kwek DJ, Barkham T, Yang H, Renia L, Leo YS, Ng LF (2011) Persistent arthralgia induced by Chikungunya virus infection is associated with interleukin-6 and granulocyte macrophage colony-stimulating factor. J Infect Dis 203:149–157 Chua CL, Sam IC, Chiam CW, Chan YF (2017) The neutralizing role of IgM during early chikungunya virus infection. PLoS One 12(2):e0171989. https://doi.org/10.1371/journal.pone.0171989 Clayton AM (2016) Monoclonal antibodies as prophylactic and therapeutic agents against chikungunya virus. J Infect Dis 214(suppl 5):S506–S509. https://doi.org/10.1093/infdis/jiw324 Coffey LL, Vasilakis N, Brault AC, Powers AM, Tripet F, Weaver SC (2008) Arbovirus evolution in vivo is constrained by host alternation. Proc Natl Acad Sci U S A 105(19):6970–6975. https://doi.org/10.1073/pnas.0712130105 Corti D, Lanzavecchia A (2013) Broadly neutralizing antiviral antibodies. Annu Rev Immunol 31:705–742. https://doi.org/10.1146/annurev-immunol-032712-095916 Couderc T, Lecuit M (2015) Chikungunya virus pathogenesis: from bedside to bench. Antivir Res 121:120–131. https://doi.org/10.1016/j.antiviral.2015.07.002 Couderc T, Chretien F, Schilte C, Disson O, Brigitte M, Guivel-Benhassine F, Touret Y, Barau G, Cayet N, Schuffenecker I, Despres P, Arenzana-Seisdedos F, Michault A, Albert ML, Lecuit M (2008) A mouse model for chikungunya: young age and inefficient type-I interferon signaling are risk factors for severe disease. PLoS Pathog 4(2):e29. https://doi.org/10.1371/journal.ppat.0040029 Couderc T, Khandoudi N, Grandadam M, Visse C, Gangneux N, Bagot S, Prost JF, Lecuit M (2009) Prophylaxis and therapy for chikungunya virus infection. J Infect Dis 200(4):516–523. https://doi.org/10.1086/600381 Couderc T, Gangneux N, Chretien F, Caro V, Le Luong T, Ducloux B, Tolou H, Lecuit M, Grandadam M (2012) Chikungunya virus infection of corneal grafts. J Infect Dis 206(6):851–859. https://doi.org/10.1093/infdis/jis296 Diallo D, Sall AA, Buenemann M, Chen R, Faye O, Diagne CT, Faye O, Ba Y, Dia I, Watts D, Weaver SC, Hanley KA, Diallo M (2012) Landscape ecology of sylvatic chikungunya virus and mosquito vectors in southeastern Senegal. PLoS Negl Trop Dis 6(6):e1649. https://doi.org/10.1371/journal.pntd.0001649 Dinkar A, Singh J, Prakash P, Das A, Nath G (2018) Hidden burden of chikungunya in North India; a prospective study in a tertiary care centre. J Infect Public Health 11(4):586–591. https://doi.org/10.1016/j.jiph.2017.09.008 Domachowske JB, Khan AA, Esser MT, Jensen K, Takas T, Villafana T, Dubovsky F, Griffin MP (2018) Safety, tolerability and pharmacokinetics of MEDI8897, an extended half-life single-dose respiratory syncytial virus prefusion F-targeting monoclonal antibody administered as a single dose to healthy preterm infants. Pediatr Infect Dis J 37(9):886–892. https://doi.org/10.1097/INF.0000000000001916 Drake JW, Holland JJ (1999) Mutation rates among RNA viruses. Proc Natl Acad Sci U S A 96(24):13910–13913. https://doi.org/10.1073/pnas.96.24.13910 Dunman PM, Nesin M (2003) Passive immunization as prophylaxis: when and where will this work? Curr Opin Pharmacol 3(5):486–496 Duperret EK, Trautz A, Stoltz R, Patel A, Wise MC, Perales-Puchalt A, Smith T, Broderick KE, Masteller E, Kim JJ, Humeau L, Muthumani K, Weiner DB (2018) Synthetic DNA-encoded monoclonal antibody delivery of anti-CTLA-4 antibodies induces tumor shrinkage in vivo. Cancer Res 78(22):6363–6370. https://doi.org/10.1158/0008-5472.CAN-18-1429 Economopoulou A, Dominguez M, Helynck B, Sissoko D, Wichmann O, Quenel P, Germonneau P, Quatresous I (2009) Atypical Chikungunya virus infections: clinical manifestations, mortality and risk factors for severe disease during the 2005-2006 outbreak on Reunion. Epidemiol Infect 137:534–541 Englund JA (2007) The influence of maternal immunization on infant immune responses. J Comp Pathol 137(Suppl 1):S16–S19. https://doi.org/10.1016/j.jcpa.2007.04.006 Erasmus JH, Rossi SL, Weaver SC (2016) Development of vaccines for chikungunya fever. J Infect Dis 214(suppl 5):S488–S496. https://doi.org/10.1093/infdis/jiw271 Fernandes AIV, Souza JR, Silva AR, Cruz S, Castellano LRC (2019) Immunoglobulin therapy in a patient with severe chikungunya fever and vesiculobullous lesions. Front Immunol 10:1498. https://doi.org/10.3389/fimmu.2019.01498 Fong RH, Banik SS, Mattia K, Barnes T, Tucker D, Liss N, Lu K, Selvarajah S, Srinivasan S, Mabila M, Miller A, Muench MO, Michault A, Rucker JB, Paes C, Simmons G, Kahle KM, Doranz BJ (2014) Exposure of epitope residues on the outer face of the chikungunya virus envelope trimer determines antibody neutralizing efficacy. J Virol 88(24):14364–14379. https://doi.org/10.1128/JVI.01943-14 Fox JM, Long F, Edeling MA, Lin H, van Duijl-Richter MKS, Fong RH, Kahle KM, Smit JM, Jin J, Simmons G, Doranz BJ, Crowe JE Jr, Fremont DH, Rossmann MG, Diamond MS (2015) Broadly neutralizing alphavirus antibodies bind an epitope on E2 and inhibit entry and egress. Cell 163(5):1095–1107. https://doi.org/10.1016/j.cell.2015.10.050 Fox JM, Roy V, Gunn BM, Huang L, Edeling MA, Mack M, Fremont DH, Doranz BJ, Johnson S, Alter G, Diamond MS (2019) Optimal therapeutic activity of monoclonal antibodies against chikungunya virus requires Fc-FcgammaR interaction on monocytes. Sci Immunol 4(32) doi:https://doi.org/10.1126/sciimmunol.aav5062 Freitas ARR, Donalisio MR, Alarcon-Elbal PM (2018) Excess mortality and causes associated with chikungunya, Puerto Rico, 2014-2015. Emerg Infect Dis 24(12):2352–2355. https://doi.org/10.3201/eid2412.170639 Fric J, Bertin-Maghit S, Wang CI, Nardin A, Warter L (2013) Use of human monoclonal antibodies to treat chikungunya virus infection. J Infect Dis 207(2):319–322. https://doi.org/10.1093/infdis/jis674 Gal-Tanamy M, Keck ZY, Yi M, McKeating JA, Patel AH, Foung SK, Lemon SM (2008) In vitro selection of a neutralization-resistant hepatitis C virus escape mutant. Proc Natl Acad Sci U S A 105(49):19450–19455. https://doi.org/10.1073/pnas.0809879105 Gardner J, Anraku I, Le TT, Larcher T, Major L, Roques P, Schroder WA, Higgs S, Suhrbier A (2010) Chikungunya virus arthritis in adult wild-type mice. J Virol 84(16):8021–8032. https://doi.org/10.1128/JVI.02603-09 Gerardin P, Barau G, Michault A, Bintner M, Randrianaivo H, Choker G, Lenglet Y, Touret Y, Bouveret A, Grivard P, Le Roux K, Blanc S, Schuffenecker I, Couderc T, Arenzana-Seisdedos F, Lecuit M, Robillard PY (2008) Multidisciplinary prospective study of mother-to-child chikungunya virus infections on the island of La Reunion. PLoS Med 5(3):e60. https://doi.org/10.1371/journal.pmed.0050060 Go YY, Balasuriya UB, Lee CK (2014) Zoonotic encephalitides caused by arboviruses: transmission and epidemiology of alphaviruses and flaviviruses. Clin Exp Vaccine Res 3(1):58–77. https://doi.org/10.7774/cevr.2014.3.1.58 Goh LY, Hobson-Peters J, Prow NA, Gardner J, Bielefeldt-Ohmann H, Pyke AT, Suhrbier A, Hall RA (2013) Neutralizing monoclonal antibodies to the E2 protein of chikungunya virus protects against disease in a mouse model. Clin Immunol 149(3):487–497. https://doi.org/10.1016/j.clim.2013.10.004 Haese NN, Broeckel RM, Hawman DW, Heise MT, Morrison TE, Streblow DN (2016) Animal models of chikungunya virus infection and disease. J Infect Dis 214(suppl 5):S482–S487. https://doi.org/10.1093/infdis/jiw284 Hallengard D, Kakoulidou M, Lulla A, Kummerer BM, Johansson DX, Mutso M, Lulla V, Fazakerley JK, Roques P, Le Grand R, Merits A, Liljestrom P (2014) Novel attenuated chikungunya vaccine candidates elicit protective immunity in C57BL/6 mice. J Virol 88(5):2858–2866. https://doi.org/10.1128/JVI.03453-13 Halstead SB (2014) Dengue antibody-dependent enhancement: knowns and unknowns. Microbiol Spectr 2(6) doi:https://doi.org/10.1128/microbiolspec.AID-0022-2014 Hamdan A, Green P, Mendelson E, Kramer MR, Pitlik S, Weinberger M (2002) Possible benefit of intravenous immunoglobulin therapy in a lung transplant recipient with West Nile virus encephalitis. Transpl Infect Dis 4(3):160–162 Hardy JL, Houk EJ, Kramer LD, Reeves WC (1983) Intrinsic factors affecting vector competence of mosquitoes for arboviruses. Annu Rev Entomol 28:229–262. https://doi.org/10.1146/annurev.en.28.010183.001305 Hawman DW, Stoermer KA, Montgomery SA, Pal P, Oko L, Diamond MS, Morrison TE (2013) Chronic joint disease caused by persistent chikungunya virus infection is controlled by the adaptive immune response. J Virol 87(24):13878–13888. https://doi.org/10.1128/JVI.02666-13 Hermanns K, Gohner C, Kopp A, Schmidt A, Merz WM, Markert UR, Junglen S, Drosten C (2018) Zika virus infection in human placental tissue explants is enhanced in the presence of dengue virus antibodies in-vitro. Emerg Microbes Infect 7(1):198. https://doi.org/10.1038/s41426-018-0199-6 Herrero LJ, Rudd PA, Liu X, Wolf S, Mahalingam S (2016) Mouse models of chikungunya virus. Methods Mol Biol 1426:211–224. https://doi.org/10.1007/978-1-4939-3618-2_19 Hey A (2015) History and practice: antibodies in infectious diseases. Microbiol Spectr 3(2):AID-0026-2014 doi:https://doi.org/10.1128/microbiolspec.AID-0026-2014 Hirano T, Taga T, Nakano N, Yasukawa K, Kashiwamura S, Shimizu K, Nakajima K, Pyun KH, Kishimoto T (1985) Purification to homogeneity and characterization of human B-cell differentiation factor (BCDF or BSFp-2). Proc Natl Acad Sci U S A 82(16):5490–5494. https://doi.org/10.1073/pnas.82.16.5490 Hoarau JJ, Jaffar Bandjee MC, Krejbich Trotot P, Das T, Li-Pat-Yuen G, Dassa B, Denizot M, Guichard E, Ribera A, Henni T, Tallet F, Moiton MP, Gauzere BA, Bruniquet S, Jaffar Bandjee Z, Morbidelli P, Martigny G, Jolivet M, Gay F, Grandadam M, Tolou H, Vieillard V, Debre P, Autran B, Gasque P (2010) Persistent chronic inflammation and infection by chikungunya arthritogenic alphavirus in spite of a robust host immune response. J Immunol 184(10):5914–5927. https://doi.org/10.4049/jimmunol.0900255 Hohdatsu T, Tokunaga J, Koyama H (1994) The role of IgG subclass of mouse monoclonal antibodies in antibody-dependent enhancement of feline infectious peritonitis virus infection of feline macrophages. Arch Virol 139(3–4):273–285 Holland J, Spindler K, Horodyski F, Grabau E, Nichol S, VandePol S (1982) Rapid evolution of RNA genomes. Science 215(4540):1577–1585. https://doi.org/10.1126/science.7041255 Jin J, Simmons G (2019) Antiviral functions of monoclonal antibodies against chikungunya virus. Viruses 11(4). https://doi.org/10.3390/v11040305 Jin J, Liss NM, Chen DH, Liao M, Fox JM, Shimak RM, Fong RH, Chafets D, Bakkour S, Keating S, Fomin ME, Muench MO, Sherman MB, Doranz BJ, Diamond MS, Simmons G (2015) Neutralizing monoclonal antibodies block chikungunya virus entry and release by targeting an epitope critical to viral pathogenesis. Cell Rep 13(11):2553–2564. https://doi.org/10.1016/j.celrep.2015.11.043 Johnson BJ, Brubaker JR, Roehrig JT, Trent DW (1990) Variants of Venezuelan equine encephalitis virus that resist neutralization define a domain of the E2 glycoprotein. Virology 177(2):676–683 Johnson PR, Schnepp BC, Zhang J, Connell MJ, Greene SM, Yuste E, Desrosiers RC, Clark KR (2009) Vector-mediated gene transfer engenders long-lived neutralizing activity and protection against SIV infection in monkeys. Nat Med 15(8):901–906. https://doi.org/10.1038/nm.1967 Josseran L, Paquet C, Zehgnoun A, Caillere N, Le Tertre A, Solet JL, Ledrans M (2006) Chikungunya disease outbreak, Reunion Island. Emerg Infect Dis 12:1994–1995 Kam YW, Lee WW, Simarmata D, Harjanto S, Teng TS, Tolou H, Chow A, Lin RT, Leo YS, Renia L, Ng LF (2012a) Longitudinal analysis of the human antibody response to chikungunya virus infection: implications for serodiagnosis and vaccine development. J Virol 86(23):13005–13015. https://doi.org/10.1128/JVI.01780-12 Kam YW, Lum FM, Teo TH, Lee WW, Simarmata D, Harjanto S, Chua CL, Chan YF, Wee JK, Chow A, Lin RT, Leo YS, Le Grand R, Sam IC, Tong JC, Roques P, Wiesmuller KH, Renia L, Rotzschke O, Ng LF (2012b) Early neutralizing IgG response to chikungunya virus in infected patients targets a dominant linear epitope on the E2 glycoprotein. EMBO Mol Med 4(4):330–343. https://doi.org/10.1002/emmm.201200213 Kam YW, Simarmata D, Chow A, Her Z, Teng TS, Ong EK, Renia L, Leo YS, Ng LF (2012c) Early appearance of neutralizing immunoglobulin G3 antibodies is associated with chikungunya virus clearance and long-term clinical protection. J Infect Dis 205(7):1147–1154. https://doi.org/10.1093/infdis/jis033 Kam YW, Pok KY, Eng KE, Tan LK, Kaur S, Lee WW, Leo YS, Ng LC, Ng LF (2015) Sero-prevalence and cross-reactivity of chikungunya virus specific anti-E2EP3 antibodies in arbovirus-infected patients. PLoS Negl Trop Dis 9(1):e3445. https://doi.org/10.1371/journal.pntd.0003445 Kashyap RS, Morey SH, Chandak NH, Purohit HJ, Taori GM, Daginawala HF (2010) Detection of viral antigen, IgM and IgG antibodies in cerebrospinal fluid of Chikungunya patients with neurological complications. Cerebrospinal Fluid Res 7:12 Kawano Y, Noma T, Yata J (1994) Regulation of human IgG subclass production by cytokines. IFN-gamma and IL-6 act antagonistically in the induction of human IgG1 but additively in the induction of IgG2. J Immunol 153(11):4948–4958 Kielian M, Saphire EO (2015) Potent antibody protection against an emerging alphavirus threat. Cell 163(5):1053–1054. https://doi.org/10.1016/j.cell.2015.11.006 Kim J, Yang J, Kim YB, Lee HJ, Kim S, Poo H (2019) Development of a specific CHIKV-E2 monoclonal antibody for chikungunya diagnosis. Virol Sin. https://doi.org/10.1007/s12250-019-00135-y King AA, Sands JJ, Porterfield JS (1984) Antibody-mediated enhancement of rabies virus infection in a mouse macrophage cell line (P388D1). J Gen Virol 65(Pt 6):1091–1093. https://doi.org/10.1099/0022-1317-65-6-1091 Kose N, Fox JM, Sapparapu G, Bombardi R, Tennekoon RN, de Silva AD, Elbashir SM, Theisen MA, Humphris-Narayanan E, Ciaramella G, Himansu S, Diamond MS, Crowe JE Jr (2019) A lipid-encapsulated mRNA encoding a potently neutralizing human monoclonal antibody protects against chikungunya infection. Sci Immunol 4(35). https://doi.org/10.1126/sciimmunol.aaw6647 Krishnamoorthy K, Harichandrakumar KT, Krishna Kumari A, Das LK (2009) Burden of chikungunya in India: estimates of disability adjusted life years (DALY) lost in 2006 epidemic. J Vector Borne Dis 46(1):26–35 Kumar R, Qureshi H, Deshpande S, Bhattacharya J (2018) Broadly neutralizing antibodies in HIV-1 treatment and prevention. Ther Adv Vaccines Immunother 6(4):61–68. https://doi.org/10.1177/2515135518800689 Labadie K, Larcher T, Joubert C, Mannioui A, Delache B, Brochard P, Guigand L, Dubreil L, Lebon P, Verrier B, de Lamballerie X, Suhrbier A, Cherel Y, Le Grand R, Roques P (2010) Chikungunya disease in nonhuman primates involves long-term viral persistence in macrophages. J Clin Invest 120(3):894–906. https://doi.org/10.1172/JCI40104 Lam S, Nyo M, Phuektes P, Yew CW, Tan YJ, Chu JJ (2015) A potent neutralizing IgM mAb targeting the N218 epitope on E2 protein protects against chikungunya virus pathogenesis. MAbs 7(6):1178–1194. https://doi.org/10.1080/19420862.2015.1083664 Landry ML (2016) Immunoglobulin M for acute infection: true or false? Clin Vaccine Immunol 23(7):540–545. https://doi.org/10.1128/CVI.00211-16 Langerak T, Mumtaz N, Tolk VI, van Gorp ECM, Martina BE, Rockx B, Koopmans MPG (2019) The possible role of cross-reactive dengue virus antibodies in Zika virus pathogenesis. PLoS Pathog 15(4):e1007640. https://doi.org/10.1371/journal.ppat.1007640 Lee CY, Kam YW, Fric J, Malleret B, Koh EG, Prakash C, Huang W, Lee WW, Lin C, Lin RT, Renia L, Wang CI, Ng LF, Warter L (2011) Chikungunya virus neutralization antigens and direct cell-to-cell transmission are revealed by human antibody-escape mutants. PLoS Pathog 7(12):e1002390. https://doi.org/10.1371/journal.ppat.1002390 Levade M, Maquin P, Rousseau H, Trocard J, Railhac JJ, Joffre F (1991) Percutaneous peripheral atherectomy with the Simpson catheter. Long term results. J Mal Vasc 16(2):193–194 Lidbury BA, Mahalingam S (2000) Specific ablation of antiviral gene expression in macrophages by antibody-dependent enhancement of Ross River virus infection. J Virol 74(18):8376–8381. https://doi.org/10.1128/jvi.74.18.8376-8381.2000 Lim BN, Tye GJ, Choong YS, Ong EB, Ismail A, Lim TS (2014) Principles and application of antibody libraries for infectious diseases. Biotechnol Lett 36(12):2381–2392. https://doi.org/10.1007/s10529-014-1635-x Lin YS, Yeh TM, Lin CF, Wan SW, Chuang YC, Hsu TK, Liu HS, Liu CC, Anderson R, Lei HY (2011) Molecular mimicry between virus and host and its implications for dengue disease pathogenesis. Exp Biol Med (Maywood) 236:515–523 Lin SC, Shyur SD, Ma YC, Huang LH, Lee WI (2005) Hyper-IgM1 syndrome with interstitial pneumonia and diarrhea caused by coxsackievirus B4 in a 3-month-old infant. Ann Allergy Asthma Immunol 95(1):93–97. https://doi.org/10.1016/S1081-1206(10)61194-5 Liu M, Yang G, Wiehe K, Nicely NI, Vandergrift NA, Rountree W, Bonsignori M, Alam SM, Gao J, Haynes BF, Kelsoe G (2015) Polyreactivity and autoreactivity among HIV-1 antibodies. J Virol 89(1):784–798. https://doi.org/10.1128/JVI.02378-14 Liu JL, Shriver-Lake LC, Zabetakis D, Anderson GP, Goldman ER (2019) Selection and characterization of protective anti-chikungunya virus single domain antibodies. Mol Immunol 105:190–197. https://doi.org/10.1016/j.molimm.2018.11.016 Long F, Fong RH, Austin SK, Chen Z, Klose T, Fokine A, Liu Y, Porta J, Sapparapu G, Akahata W, Doranz BJ, Crowe JE Jr, Diamond MS, Rossmann MG (2015) Cryo-EM structures elucidate neutralizing mechanisms of anti-chikungunya human monoclonal antibodies with therapeutic activity. Proc Natl Acad Sci U S A 112(45):13898–13903. https://doi.org/10.1073/pnas.1515558112 Lum FM, Couderc T, Chia BS, Ong RY, Her Z, Chow A, Leo YS, Kam YW, Renia L, Lecuit M, Ng LFP (2018) Antibody-mediated enhancement aggravates chikungunya virus infection and disease severity. Sci Rep 8(1):1860. https://doi.org/10.1038/s41598-018-20305-4 Malvy D, Ezzedine K, Mamani-Matsuda M, Autran B, Tolou H, Receveur MC, Pistone T, Rambert J, Moynet D, Mossalayi D (2009) Destructive arthritis in a patient with chikungunya virus infection with persistent specific IgM antibodies. BMC Infect Dis 9:200. https://doi.org/10.1186/1471-2334-9-200 Marston HD, Paules CI, Fauci AS (2018) Monoclonal antibodies for emerging infectious diseases - borrowing from history. N Engl J Med 378:1469–1472 Masrinoul P, Puiprom O, Tanaka A, Kuwahara M, Chaichana P, Ikuta K, Ramasoota P, Okabayashi T (2014) Monoclonal antibody targeting chikungunya virus envelope 1 protein inhibits virus release. Virology 464-465:111–117. https://doi.org/10.1016/j.virol.2014.05.038 Matusali G, Colavita F, Bordi L, Lalle E, Ippolito G, Capobianchi MR, Castilletti C (2019) Tropism of the chikungunya virus. Viruses 11(2). https://doi.org/10.3390/v11020175 Mavalankar D, Shastri P, Bandyopadhyay T, Parmar J, Ramani KV (2008) Increased mortality rate associated with chikungunya epidemic, Ahmedabad, India. Emerg Infect Dis 14(3):412–415. https://doi.org/10.3201/eid1403.070720 Metz SW, Gardner J, Geertsema C, Le TT, Goh L, Vlak JM, Suhrbier A, Pijlman GP (2013) Effective chikungunya virus-like particle vaccine produced in insect cells. PLoS Negl Trop Dis 7(3):e2124. https://doi.org/10.1371/journal.pntd.0002124 Midgley CM, Flanagan A, Tran HB, Dejnirattisai W, Chawansuntati K, Jumnainsong A, Wongwiwat W, Duangchinda T, Mongkolsapaya J, Grimes JM, Screaton GR (2012) Structural analysis of a dengue cross-reactive antibody complexed with envelope domain III reveals the molecular basis of cross-reactivity. J Immunol 188(10):4971–4979. https://doi.org/10.4049/jimmunol.1200227 Miner JJ, Cook LE, Hong JP, Smith AM, Richner JM, Shimak RM, Young AR, Monte K, Poddar S, Crowe JE Jr, Lenschow DJ, Diamond MS (2017) Therapy with CTLA4-Ig and an antiviral monoclonal antibody controls chikungunya virus arthritis. Sci Transl Med 9(375). https://doi.org/10.1126/scitranslmed.aah3438 Morens DM, Halstead SB (1990) Measurement of antibody-dependent infection enhancement of four dengue virus serotypes by monoclonal and polyclonal antibodies. J Gen Virol 71(Pt 12):2909–2914. https://doi.org/10.1099/0022-1317-71-12-2909 Mothes W, Sherer NM, Jin J, Zhong P (2010) Virus cell-to-cell transmission. J Virol 84(17):8360–8368. https://doi.org/10.1128/JVI.00443-10 Muller T, Dietzschold B, Ertl H, Fooks AR, Freuling C, Fehlner-Gardiner C, Kliemt J, Meslin FX, Franka R, Rupprecht CE, Tordo N, Wanderler AI, Kieny MP (2009) Development of a mouse monoclonal antibody cocktail for post-exposure rabies prophylaxis in humans. PLoS Negl Trop Dis 3(11):e542. https://doi.org/10.1371/journal.pntd.0000542 Muthumani K, Block P, Flingai S, Muruganantham N, Chaaithanya IK, Tingey C, Wise M, Reuschel EL, Chung C, Muthumani A, Sarangan G, Srikanth P, Khan AS, Vijayachari P, Sardesai NY, Kim JJ, Ugen KE, Weiner DB (2016) Rapid and Long-term immunity elicited by DNA-encoded antibody prophylaxis and DNA vaccination against chikungunya virus. J Infect Dis 214(3):369–378. https://doi.org/10.1093/infdis/jiw111 Nakayama E, Tomabechi D, Matsuno K, Kishida N, Yoshida R, Feldmann H, Takada A (2011) Antibody-dependent enhancement of Marburg virus infection. J Infect Dis 204(Suppl 3):S978–S985. https://doi.org/10.1093/infdis/jir334 Ng JK, Zhang SL, Tan HC, Yan B, Martinez JM, Tan WY, Lam JH, Tan GK, Ooi EE, Alonso S (2014) First experimental in vivo model of enhanced dengue disease severity through maternally acquired heterotypic dengue antibodies. PLoS Pathog 10(4):e1004031. https://doi.org/10.1371/journal.ppat.1004031 Nitatpattana N, Kanjanopas K, Yoksan S, Satimai W, Vongba N, Langdatsuwan S, Nakgoi K, Ratchakum S, Wauquier N, Souris M, Auewarakul P, Gonzalez JP (2014) Long-term persistence of chikungunya virus neutralizing antibodies in human populations of north eastern Thailand. Virol J 11:183. https://doi.org/10.1186/1743-422X-11-183 Ochiai H, Kurokawa M, Matsui S, Yamamoto T, Kuroki Y, Kishimoto C, Shiraki K (1992) Infection enhancement of influenza A NWS virus in primary murine macrophages by anti-hemagglutinin monoclonal antibody. J Med Virol 36(3):217–221 Pal P, Dowd KA, Brien JD, Edeling MA, Gorlatov S, Johnson S, Lee I, Akahata W, Nabel GJ, Richter MK, Smit JM, Fremont DH, Pierson TC, Heise MT, Diamond MS (2013) Development of a highly protective combination monoclonal antibody therapy against chikungunya virus. PLoS Pathog 9(4):e1003312. https://doi.org/10.1371/journal.ppat.1003312 Pal P, Fox JM, Hawman DW, Huang YJ, Messaoudi I, Kreklywich C, Denton M, Legasse AW, Smith PP, Johnson S, Axthelm MK, Vanlandingham DL, Streblow DN, Higgs S, Morrison TE, Diamond MS (2014) Chikungunya viruses that escape monoclonal antibody therapy are clinically attenuated, stable, and not purified in mosquitoes. J Virol 88(15):8213–8226. https://doi.org/10.1128/JVI.01032-14 Palmeira P, Quinello C, Silveira-Lessa AL, Zago CA, Carneiro-Sampaio M (2012) IgG placental transfer in healthy and pathological pregnancies. Clin Dev Immunol 2012:985646. https://doi.org/10.1155/2012/985646 Parashar D, Cherian S (2014) Antiviral perspectives for chikungunya virus. Biomed Res Int 2014:631642. https://doi.org/10.1155/2014/631642 Pardi N, Secreto AJ, Shan X, Debonera F, Glover J, Yi Y, Muramatsu H, Ni H, Mui BL, Tam YK, Shaheen F, Collman RG, Kariko K, Danet-Desnoyers GA, Madden TD, Hope MJ, Weissman D (2017) Administration of nucleoside-modified mRNA encoding broadly neutralizing antibody protects humanized mice from HIV-1 challenge. Nat Commun 8:14630. https://doi.org/10.1038/ncomms14630 Parola P, de Lamballerie X, Jourdan J, Rovery C, Vaillant V, Minodier P, Brouqui P, Flahault A, Raoult D, Charrel RN (2006) Novel chikungunya virus variant in travelers returning from Indian Ocean islands. Emerg Infect Dis 12(10):1493–1499. https://doi.org/10.3201/eid1210.060610 Patil S, Kumar R, Deshpande S, Samal S, Shrivastava T, Boliar S, Bansal M, Chaudhary NK, Srikrishnan AK, Murugavel KG, Solomon S, Simek M, Koff WC, Goyal R, Chakrabarti BK, Bhattacharya J (2016) Conformational epitope-specific broadly neutralizing plasma antibodies obtained from an HIV-1 clade C-infected elite neutralizer mediate autologous virus escape through mutations in the V1 loop. J Virol 90(7):3446–3457. https://doi.org/10.1128/JVI.03090-15 Pelfrene E, Mura M, Cavaleiro Sanches A, Cavaleri M (2018) Monoclonal antibodies as anti-infective products: a promising future? Clin Microbiol Infect. https://doi.org/10.1016/j.cmi.2018.04.024 Petitdemange C, Wauquier N, Vieillard V (2015) Control of immunopathology during chikungunya virus infection. J Allergy Clin Immunol 135(4):846–855. https://doi.org/10.1016/j.jaci.2015.01.039 Pierro A, Rossini G, Gaibani P, Finarelli AC, Moro ML, Landini MP, Sambri V (2015) Persistence of anti-chikungunya virus-specific antibodies in a cohort of patients followed from the acute phase of infection after the 2007 outbreak in Italy. New Microbes New Infect 7:23–25. https://doi.org/10.1016/j.nmni.2015.04.002 Piper A, Ribeiro M, Smith KM, Briggs CM, Huitt E, Nanda K, Spears CJ, Quiles M, Cullen J, Thomas ME, Brown DT, Hernandez R (2013) Chikungunya virus host range E2 transmembrane deletion mutants induce protective immunity against challenge in C57BL/6J mice. J Virol 87(12):6748–6757. https://doi.org/10.1128/JVI.03357-12 Plante K, Wang E, Partidos CD, Weger J, Gorchakov R, Tsetsarkin K, Borland EM, Powers AM, Seymour R, Stinchcomb DT, Osorio JE, Frolov I, Weaver SC (2011) Novel chikungunya vaccine candidate with an IRES-based attenuation and host range alteration mechanism. PLoS Pathog 7(7):e1002142. https://doi.org/10.1371/journal.ppat.1002142 Porterfield JS (1981) Antibody-mediated enhancement of rabies virus. Nature 290(5807):542. https://doi.org/10.1038/290542a0 Powers AM (2018) Vaccine and therapeutic options to control chikungunya virus. Clin Microbiol Rev 31(1). https://doi.org/10.1128/CMR.00104-16 Powers AM, Logue CH (2007) Changing patterns of chikungunya virus: re-emergence of a zoonotic arbovirus. J Gen Virol 88(Pt 9):2363–2377. https://doi.org/10.1099/vir.0.82858-0 Qiao X, He B, Chiu A, Knowles DM, Chadburn A, Cerutti A (2006) Human immunodeficiency virus 1 Nef suppresses CD40-dependent immunoglobulin class switching in bystander B cells. Nat Immunol 7(3):302–310. https://doi.org/10.1038/ni1302 Reddy V, Desai A, Krishna SS, Vasanthapuram R (2017) Molecular mimicry between Chikungunya virus and host components: a possible mechanism for the arthritic manifestations. PLoS Negl Trop Dis 11:e0005238 Rezza G (2015) Do we need a vaccine against chikungunya? Pathog Glob Health 109(4):170–173. https://doi.org/10.1179/2047773215Y.0000000017 Rezza G (2018) Chikungunya is back in Italy: 2007-2017. J Travel Med 25(1). https://doi.org/10.1093/jtm/tay004 Rezza G, Weaver SC (2019) Chikungunya as a paradigm for emerging viral diseases: evaluating disease impact and hurdles to vaccine development. PLoS Negl Trop Dis 13(1):e0006919. https://doi.org/10.1371/journal.pntd.0006919 Robinson MC (1955) An epidemic of virus disease in Southern Province, Tanganyika territory, in 1952-53. I Clinical features. Trans R Soc Trop Med Hyg 49(1):28–32. https://doi.org/10.1016/0035-9203(55)90080-8 Robinson WE Jr, Montefiori DC, Mitchell WM (1988) Antibody-dependent enhancement of human immunodeficiency virus type 1 infection. Lancet 1(8589):790–794. https://doi.org/10.1016/s0140-6736(88)91657-1 Rosen L, Shroyer DA, Tesh RB, Freier JE, Lien JC (1983) Transovarial transmission of dengue viruses by mosquitoes: Aedes albopictus and Aedes aegypti. Am J Trop Med Hyg 32(5):1108–1119. https://doi.org/10.4269/ajtmh.1983.32.1108 Ross RW (1956) The Newala epidemic. III. The virus: isolation, pathogenic properties and relationship to the epidemic. J Hyg (Lond) 54(2):177–191. https://doi.org/10.1017/s0022172400044442 Rosso F, Rodriguez S, Cedano JA, Mora BL, Moncada PA, Velez JD (2018) Chikungunya in solid organ transplant recipients, a case series and literature review. Transpl Infect Dis 20(6):e12978. https://doi.org/10.1111/tid.12978 Rothan HA, Bidokhti MRM, Byrareddy SN (2018) Current concerns and perspectives on Zika virus co-infection with arboviruses and HIV. J Autoimmun 89:11–20. https://doi.org/10.1016/j.jaut.2018.01.002 Runowska M, Majewski D, Niklas K, Puszczewicz M (2018) Chikungunya virus: a rheumatologist's perspective. Clin Exp Rheumatol 36(3):494–501 Sa PKO, Nunes MM, Leite IR, Campelo M, Leao CFR, Souza JR, Castellano LR, Fernandes AIV (2017) Chikungunya virus infection with severe neurologic manifestations: report of four fatal cases. Rev Soc Bras Med Trop 50:265–268 Safaeian M, Porras C, Pan Y, Kreimer A, Schiller JT, Gonzalez P, Lowy DR, Wacholder S, Schiffman M, Rodriguez AC, Herrero R, Kemp T, Shelton G, Quint W, van Doorn LJ, Hildesheim A, Pinto LA, Group CVT (2013) Durable antibody responses following one dose of the bivalent human papillomavirus L1 virus-like particle vaccine in the Costa Rica Vaccine Trial. Cancer Prev Res (Phila) 6(11):1242–1250. https://doi.org/10.1158/1940-6207.CAPR-13-0203 Senanayake MP, Senanayake SM, Vidanage KK, Gunasena S, Lamabadusuriya SP (2009) Vertical transmission in chikungunya infection. Ceylon Med J 54:47–50 Schiller J, Chackerian B (2014) Why HIV virions have low numbers of envelope spikes: implications for vaccine development. PLoS Pathog 10(8):e1004254. https://doi.org/10.1371/journal.ppat.1004254 Scott SSO, Braga-Neto P, Pereira LP, Nobrega PR, de Assis Aquino Gondim F, Sobreira-Neto MA, Schiavon CCM (2017) Immunoglobulin-responsive chikungunya encephalitis: two case reports. J Neuro-Oncol 23(4):625–631. https://doi.org/10.1007/s13365-017-0535-y Selvarajah S, Sexton NR, Kahle KM, Fong RH, Mattia KA, Gardner J, Lu K, Liss NM, Salvador B, Tucker DF, Barnes T, Mabila M, Zhou X, Rossini G, Rucker JB, Sanders DA, Suhrbier A, Sambri V, Michault A, Muench MO, Doranz BJ, Simmons G (2013) A neutralizing monoclonal antibody targeting the acid-sensitive region in chikungunya virus E2 protects from disease. PLoS Negl Trop Dis 7(9):e2423. https://doi.org/10.1371/journal.pntd.0002423 Simon F, Javelle E, Cabie A, Bouquillard E, Troisgros O, Gentile G, Leparc-Goffart I, Hoen B, Gandjbakhch F, Rene-Corail P, Franco JM, Caumes E, Combe B, Poiraudeau S, Gane-Troplent F, Djossou F, Schaerverbeke T, Criquet-Hayot A, Carrere P, Malvy D, Gaillard P, Wendling D, Societe de pathologie infectieuse de langue f (2015) French guidelines for the management of chikungunya (acute and persistent presentations). November 2014. Med Mal Infect 45(7):243–263. https://doi.org/10.1016/j.medmal.2015.05.007 Sitati E, McCandless EE, Klein RS, Diamond MS (2007) CD40-CD40 ligand interactions promote trafficking of CD8+ T cells into the brain and protection against West Nile virus encephalitis. J Virol 81(18):9801–9811. https://doi.org/10.1128/JVI.00941-07 Smith SA, Silva LA, Fox JM, Flyak AI, Kose N, Sapparapu G, Khomandiak S, Ashbrook AW, Kahle KM, Fong RH, Swayne S, Doranz BJ, McGee CE, Heise MT, Pal P, Brien JD, Austin SK, Diamond MS, Dermody TS, Crowe JE Jr (2015) Isolation and characterization of broad and ultrapotent human monoclonal antibodies with therapeutic activity against chikungunya virus. Cell Host Microbe 18(1):86–95. https://doi.org/10.1016/j.chom.2015.06.009 Sparrow E, Friede M, Sheikh M, Torvaldsen S (2017) Therapeutic antibodies for infectious diseases. Bull World Health Organ 95(3):235–237. https://doi.org/10.2471/BLT.16.178061 Srinivasan SGM, Maity S, Varadarajan R (2016) Broadly neutralizing antibodies for therapy of viral infections. Antibody Technol J 6:1–15 Stec DS, Waddell A, Schmaljohn CS, Cole GA, Schmaljohn AL (1986) Antibody-selected variation and reversion in Sindbis virus neutralization epitopes. J Virol 57(3):715–720 Suhrbier A, Jaffar-Bandjee MC, Gasque P (2012) Arthritogenic alphaviruses--an overview. Nat Rev Rheumatol 8(7):420–429. https://doi.org/10.1038/nrrheum.2012.64 Sun S, Xiang Y, Akahata W, Holdaway H, Pal P, Zhang X, Diamond MS, Nabel GJ, Rossmann MG (2013) Structural analyses at pseudo atomic resolution of chikungunya virus and antibodies show mechanisms of neutralization. Elife 2:e00435. https://doi.org/10.7554/eLife.00435 Sun H, Chen Q, Lai H (2017) Development of antibody therapeutics against flaviviruses. Int J Mol Sci 19(1). https://doi.org/10.3390/ijms19010054 Takada A, Kawaoka Y (2003) Antibody-dependent enhancement of viral infection: molecular mechanisms and in vivo implications. Rev Med Virol 13(6):387–398. https://doi.org/10.1002/rmv.405 Tan CH, Wong PS, Li MZ, Tan SY, Lee TK, Pang SC, Lam-Phua SG, Maideen N, Png AB, Koou SY, Lu D, Ng LC (2011) Entomological investigation and control of a chikungunya cluster in Singapore. Vector Borne Zoonotic Dis 11(4):383–390. https://doi.org/10.1089/vbz.2010.0022 Tanabe ISB, Tanabe ELL, Santos EC, Martins WV, Araujo I, Cavalcante MCA, Lima ARV, Camara NOS, Anderson L, Yunusov D, Bassi EJ (2018) Cellular and molecular immune response to chikungunya virus infection. Front Cell Infect Microbiol 8:345. https://doi.org/10.3389/fcimb.2018.00345 Tang BL (2012) The cell biology of Chikungunya virus infection. Cell Microbiol 14:1354–1363 Tharmarajah K, Mahalingam S, Zaid A (2017) Chikungunya: vaccines and therapeutics. F1000Res 6:2114. https://doi.org/10.12688/f1000research.12461.1 Tsetsarkin KA, Vanlandingham DL, McGee CE, Higgs S (2007) A single mutation in chikungunya virus affects vector specificity and epidemic potential. PLoS Pathog 3(12):e201. https://doi.org/10.1371/journal.ppat.0030201 Vijayakumar KP, Nair Anish TS, George B, Lawrence T, Muthukkutty SC, Ramachandran R (2011) Clinical profile of chikungunya patients during the epidemic of 2007 in Kerala, India. J Global Infect Dis 3(3):221–226. https://doi.org/10.4103/0974-777X.83526 Volk SM, Chen R, Tsetsarkin KA, Adams AP, Garcia TI, Sall AA, Nasar F, Schuh AJ, Holmes EC, Higgs S, Maharaj PD, Brault AC, Weaver SC (2010) Genome-scale phylogenetic analyses of chikungunya virus reveal independent emergences of recent epidemics and various evolutionary rates. J Virol 84(13):6497–6504. https://doi.org/10.1128/JVI.01603-09 Vollmers HP, Brandlein S (2005) The "early birds": natural IgM antibodies and immune surveillance. Histol Histopathol 20(3):927–937. https://doi.org/10.14670/HH-20.927 Vrati S, Fernon CA, Dalgarno L, Weir RC (1988) Location of a major antigenic site involved in Ross River virus neutralization. Virology 162(2):346–353 Warter L, Lee CY, Thiagarajan R, Grandadam M, Lebecque S, Lin RT, Bertin-Maghit S, Ng LF, Abastado JP, Despres P, Wang CI, Nardin A (2011) Chikungunya virus envelope-specific human monoclonal antibodies with broad neutralization potency. J Immunol 186(5):3258–3264. https://doi.org/10.4049/jimmunol.1003139 Weaver SC, Osorio JE, Livengood JA, Chen R, Stinchcomb DT (2012) Chikungunya virus and prospects for a vaccine. Expert Rev Vaccines 11(9):1087–1101. https://doi.org/10.1586/erv.12.84 Weber C, Berberich E, von Rhein C, Henss L, Hildt E, Schnierle BS (2017) Identification of functional determinants in the chikungunya virus E2 protein. PLoS Negl Trop Dis 11(1):e0005318. https://doi.org/10.1371/journal.pntd.0005318 Wong HV, Vythilingam I, Sulaiman WY, Lulla A, Merits A, Chan YF, Sam IC (2016) Detection of persistent chikungunya virus RNA but not infectious virus in experimental vertical transmission in Aedes aegypti from Malaysia. Am J Trop Med Hyg 94(1):182–186. https://doi.org/10.4269/ajtmh.15-0318 Yap G, Pok KY, Lai YL, Hapuarachchi HC, Chow A, Leo YS, Tan LK, Ng LC (2010) Evaluation of chikungunya diagnostic assays: differences in sensitivity of serology assays in two independent outbreaks. PLoS Negl Trop Dis 4(7):e753. https://doi.org/10.1371/journal.pntd.0000753 Young AR, Locke MC, Cook LE, Hiller BE, Zhang R, Hedberg ML, Monte KJ, Veis DJ, Diamond MS, Lenschow DJ (2019) Dermal and muscle fibroblasts and skeletal myofibers survive chikungunya virus infection and harbor persistent RNA. PLoS Pathog 15:e1007993 Ziegler SA, Lu L, da Rosa AP, Xiao SY, Tesh RB (2008) An animal model for studying the pathogenesis of chikungunya virus infection. Am J Trop Med Hyg 79(1):133–139